Skip to main content
Reported segment mix · SEC DERA dimensional facts

Onconetix, Inc. ONCO revenue by segment, product and geography

In its fiscal year ending 2025-12-31, Onconetix, Inc. reported revenue across 4 products and services; the largest, Other Revenues, was $588K, 72.1% of the filed sum.

Reported segment mix

figures as filed · share of the filed sum · change vs the prior period in the same filing
Fiscal year ending 2025-12-3110-K filed 2026-03-13prior period 2024-12-31 from the same filingView filing
By product or service
Revenue
  • Other Revenues$588K
    72.1%
    no prior
  • Product Sales$226K
    27.7%
    -9.3% yoy
  • Development Service$1.65K
    0.2%
    -99.9% yoy
  • License$0.6
    0.0%
    no prior

Members sum to the consolidated $815K for this period.

By geography
Revenue
  • Switzerland$797K
    share n/a
    -67.3% yoy
  • European Union$797K
    share n/a
    -67.3% yoy
  • Non European Union$18.8K
    share n/a
    -21.2% yoy
  • United Kingdom$18.8K
    share n/a
    -21.2% yoy

member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.

Latest quarter
Quarter ending 2026-03-3110-Q filed 2026-05-13prior period 2025-03-31 from the same filingView filing
  • United Kingdom$21.5K
    100.0%
    +196.1% yoy

Change is against the same quarter a year earlier, as reported in the same 10-Q.

Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.

About these figures

Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.

Descriptive and educational; not investment advice. Methodology and data lineage.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.

Onconetix, Inc. (ONCO) revenue by segment, product and geography FY2025 | TrendNalysis